Royalty Pharma.
biopharmaceutical company based in New York City
- Reports this week
- 1
- Active events
- 3
- Connections
- 52
What's happening
Active this week
-
Visteon filed transaction details with the SEC and traded on the Nasdaq stock exchange on June 6, 2026.Some support6 reports
-
Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Well supported9 reports
-
Royalty Pharma's CFO discussed policy risks affecting company strategy, and the company hired an executive from Goldman Sachs for its China team.Some support1 report
Earlier this month
-
Pablo Legorreta was named the founder and CEO of Royalty Pharma, which provides funding in exchange for royalty rights.Well supported9 reports
-
Royalty Pharma outperformed the market so far this year, based on data from August 6, 2025.Some support1 report1 development inside
-
Novartis' trial results are impacting Royalty Pharma's investment decisions.Some support1 report
-
Stock trading activity for multiple companies, including Royalty Pharma, TTM Technologies, Trane Technologies, and others, was reported on the Nasdaq exchange on August 30, 2026.Some support1 report
One to three months ago
-
Bank of America reissued a buy rating and Morgan Stanley lifted the price target for Royalty Pharma.Some support1 report
-
Royalty Pharma acquired a royalty interest in AstraZeneca's cliramitug.Some support4 reports
-
Citigroup, Morgan Stanley, and TD Cowen have raised their price targets and upgraded ratings for Royalty Pharma, with filings made public via the SEC.Some support3 reports
-
Royalty Pharma filed a prospectus with the Securities and Exchange Commission on September 3, 2025.Well supported5 reports
Gone quiet
No new reports in 90+ days-
Royalty Pharma is headquartered in New York City and opened its first Asia-Pacific base in Hong Kong, while Kenneth Sun moved from Morgan Stanley to the company.Some support1 report
-
Trump pledged to unleash American oil and gas, involving Royalty Pharma.Some support1 report
-
Kadant, News Corp, Cencora, and Royalty Pharma were identified as high-quality stocks operating in the pharmaceutical industry.Speculative1 report
-
Buffett described how share prices do not reflect business value, discussing the role of TSR and dividends in the context of Royalty Pharma.Speculative2 reports
-
Royalty Pharma enhanced its governance structure following an acquisition by an external manager.Some support1 report
-
Morgan Stanley raised its price target for Royalty Pharma, noting regulatory uncertainty and the impact of tariffs.Some support1 report
-
Peter Lynch's advice contrasts with the focus on profitable companies regarding Royalty Pharma.Some support1 report
-
Revolution Medicines received Breakthrough Therapy Designation and entered into a major funding agreement, while activating international clinical trials in Europe and Japan.Some support4 reports
-
Royalty Pharma holds royalty rights for products developed by GSK, Biogen, and AbbVie.Some support5 reports
No events began in the chosen period. Widen it, or reset.
Around Royalty Pharma this week
News at the entities that move Royalty Pharma most-
AbbVie StructuralAbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Moves Royalty Pharma
-
Amgen StructuralAmgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Moves Royalty Pharma
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Royalty Pharma
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Royalty Pharma
-
GSK StructuralClement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.Moves Royalty Pharma
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Royalty Pharma
Connections
The 26 strongest of 52, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Morgan Stanley Operational
Morgan Stanley actively covers, rates, and invests in Royalty Pharma, linking the two through market analysis and capital allocation.
-
AbbVie Structural
Royalty Pharma holds ongoing royalty rights to AbbVie's products, generating revenue from AbbVie's sales.
-
Pablo Legorreta Structural
Pablo Legorreta is the founder and CEO of Royalty Pharma.
-
Securities and Exchange Commission Structural
Royalty Pharma must comply with formal regulatory filing requirements set by the SEC.
-
Amgen Structural
Royalty Pharma holds royalty rights to Amgen's drugs, establishing a persistent financial dependency on Amgen's sales.
-
Terry Coyne Structural
Terry Coyne serves as the Chief Financial Officer of Royalty Pharma.
-
Theravance Biopharma (United States) Transactional
Theravance expects and receives milestone payments from Royalty Pharma based on financial agreements.
-
Zenas Transactional
Royalty Pharma provided funding to Zenas in exchange for a royalty on sales.
Show all 26 connections
-
Biogen Structural
Royalty Pharma receives payments and holds royalty rights on Biogen's products, supplemented by an ongoing R&D funding partnership.
-
SEC Structural
Royalty Pharma is subject to formal regulatory oversight and disclosure requirements mandated by the SEC.
-
GSK Structural
Royalty Pharma holds royalties on GSK's Trelegy, establishing a persistent financial dependency.
-
Novartis Operational
Novartis' trial results influence Royalty Pharma's investment decisions.
-
Thrivent Financial for Lutherans Transactional
Thrivent Financial for Lutherans increased its investment stake in Royalty Pharma.
-
FDA Structural
FDA regulatory decisions and uncertainty directly influence Royalty Pharma's portfolio value and investor caution.
-
Blood Cancer United Operational
The relationship is defined by a collaborative partnership between the two companies.
-
Bank of America Operational
Bank of America actively monitors Royalty Pharma by issuing buy ratings and querying deal structure importance.
-
TD Cowen Mentioned together
TD Cowen provides investment ratings and target price increases for Royalty Pharma while disclosing its share holdings.
-
Tap Transactional
Royalty Pharma is identified as the largest corporate donor to Tap.
-
AstraZeneca Transactional
Royalty Pharma acquired a royalty interest in AstraZeneca's cliramitug candidate.
-
Goldman Sachs Transactional
A specific executive from Goldman Sachs was hired for a China team.
-
Citigroup Mentioned together
Citigroup provided a positive financial rating and target price increase for Royalty Pharma.
-
MarketBeat Mentioned together
MarketBeat reports on Royalty Pharma's average stock rating and consensus target.
-
Nasdaq Shared context
Royalty Pharma is listed on the Nasdaq exchange.
-
Hong Kong Shared context
Royalty Pharma established its first Asia-Pacific base in Hong Kong.
-
Zealand Pharma Transactional
Royalty Pharma provided $100 million in funding to Zealand Pharma.
-
New York City Shared context
Royalty Pharma is headquartered in New York City.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
2 eventsJuly 2026
2 eventsShow 1 earlier month
June 2026
14 events- Visteon filed transaction details with the SEC and traded on the Nasdaq stock exchange on June 6, 2026.
- Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.
- Pablo Legorreta was named the founder and CEO of Royalty Pharma, which provides funding in exchange for royalty rights.
- Royalty Pharma outperformed the market so far this year, based on data from August 6, 2025.
- Royalty Pharma filed a prospectus with the Securities and Exchange Commission on September 3, 2025.
- Royalty Pharma is headquartered in New York City and opened its first Asia-Pacific base in Hong Kong, while Kenneth Sun moved from Morgan Stanley to the company.
- Trump pledged to unleash American oil and gas, involving Royalty Pharma.
- Kadant, News Corp, Cencora, and Royalty Pharma were identified as high-quality stocks operating in the pharmaceutical industry.
- Buffett described how share prices do not reflect business value, discussing the role of TSR and dividends in the context of Royalty Pharma.
- Royalty Pharma enhanced its governance structure following an acquisition by an external manager.
- Morgan Stanley raised its price target for Royalty Pharma, noting regulatory uncertainty and the impact of tariffs.
- Peter Lynch's advice contrasts with the focus on profitable companies regarding Royalty Pharma.
- Revolution Medicines received Breakthrough Therapy Designation and entered into a major funding agreement, while activating international clinical trials in Europe and Japan.
- Royalty Pharma holds royalty rights for products developed by GSK, Biogen, and AbbVie.